Source: Heart Future; Editor: Sophia
Reprint requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.
Recently,Medtronic (NYSE:MDT)Announce that it will launchThe New Generation Avalus Ultra Aortic Tissue Bioprosthesis.The valve'sCircular DesignYesEnable Effective Blood Flow, while the dual-component and flexible stent columns can ensureExcellent Lobular Junction。AValus Ultra is the upgraded version of Medtronic's previous surgical valve, Avalus.。Avalus Ultra Aortic Bioprosthesis Received FDA Approval in January 2024 and Is Currently Only Available in the United States。January 2022, MedtronicAvalus Bovine Pericardial Bioprosthesis Officially Approved for Marketing by NMPAThis bioprosthetic valve is a new generation of bovine pericardial aortic valve developed on the basis of 40 years of Medtronic research, and it received FDA approval for market release in 2017. The Perigon study shows,Avalus 5-YearStructural Valve Deterioration (SVD)Incidence rate is 0。
# Avalus Ultra Aortic Tissue ValveAvalus Bioprosthesis is a pericardial aortic surgical valve, establishedBuilding on the 10 years of clinical experience and long-term durability of the original Avalus valve launched in 2017.Received FDA approval in January this yearUsed to treat aortic valve stenosis，SpecificProductInformation is as follows:
1. The supra-annular design enhances hemodynamics;2. The thickness and deflection of the three laser-cut bovine pericardial leaflets are matched;3. Two-part polymer frame minimizes stress areas on the leaflet;
4. Sewing markers assist with suture placement and valve orientation.
Avalus Ultra also has the following highlights:
Durable:Polyether Ether Ketone (PEEK) Polymer ScaffoldWith good strength and flexibility, andAnti-permanent deformationThe ability;PossibleReduce the Risk of Potential Metal Corrosion in Transcatheter Stent Materials;
Good visibility:Soaked with Barium SulfateThe PEEK base frame provides radiopacity and visibility;Reduce Calcification:AdoptAOA™ Tissue Treatment Method, which can reduce calcification. It has been clinically applied in Medtronic's surgical tissue valve portfolio for over 20 years.
Easy to implant:Flexible Suture CuffConducive to penetration and valve placement, improving the implantation experience;Lower valve profile and narrow commissural postsIncreased the opening gap, providing more space;Streamlined Valve StentImproved the visibility of standards and minimally invasive approaches.
In addition to the above advantages, the design of this valveAiming to achieve 100% engagement and minimize central reflux. ValveSize, Geometric DesignIt is also expected to become an alternative for valve-in-valve (ViV).
MedtronicHeartVice President and Chief Medical Officer of Cardiac Surgery, Structural Heart, and Mechanical Circulatory SupportDr. Pieter KappeteinIndicates:“Patients with aortic valve stenosis have complex conditions, thus requiring improved surgical procedures and optimized surgical care. To address this evolving need, Medtronic has introduced innovative products such as the Avalus Ultra valve.Enhance Usability and Long-term Durability。”President of Cardiac Surgery Business, Medtronic Cardiovascular PortfolioDr. Karim BandaliIndicates:"Cardiac surgeons have long hoped that the medical industry would collaborate with them to provide improved and innovative therapies to treat patients efficiently and effectively. The Avalus Ultra valve builds on several successful innovative releases this year,I believeMedtronic will continueProceedNecessary investment,Advance the Innovative Development of Medical Devices, serving patients。”# The Billion-Dollar Bioprosthetic Valve TrackArtificial heart valves can be divided into mechanical valves and biological valves according to materials. As the first-generation artificial valve products,Patients must take anticoagulant drugs for life after mechanical valve implantation.. While the mainstream in the current market isBiological valves, while avoiding the aforementioned problems, inevitably undergo gradual calcification after implantation, with a usable lifespan of only 10 to 15 years., patients are forced to undergo a second or even third surgery.Currently, the global artificial valve market is in an oligopolistic monopoly pattern,Edwards Lifesciences, as the leader in the field, accounts for up to 60%; Medtronic follows closely with a share of about 30%.。It is worth mentioning that the core reason why Edwards remains the leader in the bioprosthetic valve field is...Improved anti-calcification technology has significantly enhanced the durability of the valve.。Anti-calcification is an important indicator for evaluating artificial biological heart valves., which is also a hot topic in the field of artificial biological valves in recent years.Currently, there are two main technical routes for animal tissue processing globally.: FirstEdward's Glutaraldehyde Cross-Linking Technology in the United States, secondlyCarboxyl Coordination Compound Crosslinking Technology Developed by Dr. Lei Jin, Founder of Balloon Medical。The former, as the core technology of Edwards valves, has multiple advantages such as being rapid, flexible, reducing immunogenicity, and the ability to bind with common amino acid residues. Currently, most bioprosthetic heart valves use glutaraldehyde for fixation to reduce immunogenicity, but this method tends to cause calcification of the bioprosthetic valve.In order to solve the calcification problem,EdwardBased on the glutaraldehyde cross-linking technology developed in 1969, it was launched in 2000.The Second-Generation Bioprosthetic Valve Anti-Calcification Technology XenoLogiX, and then developed in 2007Third-Generation Bioprosthetic Valve Anti-Calcification Technology: ThermaFix Process。At the same time, on the technical path of anti-calcification, Chinese-produced enterprises have also achieved innovative breakthroughs and made significant progress.Leader of China-Made Bioprosthetic Valves: BalRen Medical, the company's actual controller, Dr. Jin Lei, through innovative research and development, has exclusively masteredCarboxyl Coordination Compound Crosslinking Technology. According to publicly available data,This technology is even superior to glutaraldehyde cross-linking technology in some aspects.。Currently,Benn Medical has achieved multiple China-first innovations in the field of biological heart valves., filling the technical gap in China.▲Company Information DisclosureHowever, whether it isWhether mechanical or bioprosthetic valves, neither can grow with the human body." is by no means the best choice for pediatric patients.HowAddressing Bioprosthetic Valve DegenerationThis challenge, to provide patients with better and more optimal solutions?Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyProf. Dong Nianguo's team from the Department of Cardiac and Great Vessel Surgery has independently developed after more than 20 years of research.World's First New Cellularized Valve。▲Source of the imageUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyThe novel cellularized valve exhibits excellent biomechanical properties, with its surface retaining a wealth of natural active sites.After implantation in the human body, autologous cells can grow within the valve material, demonstrating a strong ability for tissue remodeling and repair.. Therefore,This valve is less prone to calcification failure, which helps patients restore pulmonary valve function.。As the world's first cellularized valve replacement, it has overcome the decay problem of traditional biological valves.Is expected to drive a fundamental shift in biomaterials from inert replacement to active regeneration., and promote the global clinical application update of bioprosthetic valves.Currently, this new type of cellular valveHas begun to enter the clinical trial stageIn 2023, Peking Union Medical College Hospital has performed seven novel cellularized valve implantation surgeries.From a clinical perspective, neither Edwards' anti-calcification technology nor the strong breakthrough of products made in China has been able to truly prevent artificial bioprosthetic valves from the ultimate fate of calcification. The fifty-year journey seems to be proving that the improvement of biomaterials is the only way out.The advent of "growable" artificial valves has triggered a fundamental transformation in biomaterials towards active regeneration, meaningAfter the Core Technology Upgrade of Biological Valves, This Golden Track May Soon Be Led by China。
Medtronic (Medtronic, NYSE: MDT) was founded in 1949, with its headquarters in Minneapolis, Minnesota, USA. It is a global leading medical technology company, employing more than 95,000 people.
Medtronic's innovative solutions have expanded to more than 70 key disease areas, committed to providing lifelong treatment options for patients with chronic conditions. Every second, two patients worldwide benefit from Medtronic's medical technology or therapies.Medtronic's main businesses includeCardiovascular, Medical Surgery, Neuroscience, and DiabetesFour business blocks, includingThe highest proportion is cardiovascular.。What Does Medtronic Sell? A Comprehensive Overview of the Cardiovascular Product Line
Taking the 2023 financial report as an example, the company's total revenue was $31.227 billion, ranking first in revenue among global medical device companies. Revenue from the cardiovascular business was $11.573 billion, accounting for 37.06%, includingCardiac Rhythm and Heart Failure (CRHF), Structural Heart and Aorta (SHA), and Coronary and Peripheral Vascular (CPV)Three departments.
▲2023 Annual Report (Source: Company Official Website)
